Revenue Growth and Upgraded Guidance
Q1 reported revenue grew 10% year-over-year with 3% organic growth (an inflection versus the prior quarter). Management raised full-year GAAP revenue guidance to $1,040M–$1,055M (reported growth >7%, organic growth up to 6%) and expects Q2 organic growth of 6%–8%.
Strong Bookings and Backlog
Bookings increased 37% year-over-year with a book-to-bill of 1.10, all businesses delivered double-digit bookings growth, and management cites a growing committed backlog supporting the 2026 outlook.
Improving Profitability
Adjusted EBITDA grew 14% year-over-year to $57M and adjusted EBITDA margin expanded by ~70 basis points to 22%. Adjusted diluted EPS was $0.81, up 9% year-over-year. Full-year adjusted EBITDA guidance $245M–$250M (+11%–13%) and adjusted EPS guidance $3.50–$3.65 (+6%–11%).
Excellent Cash Flow and Balance Sheet Position
Operating cash flow rose 63% year-over-year to $52M and cash flow conversion to net income was >200% in the quarter. Q1 cash balance was $389M, gross debt $249M, net cash position of $139M (net leverage -0.6x). The company repurchased ~$18M of stock in the quarter.
New Product Momentum and Design Wins
New product revenue grew ~50% year-over-year and the Vitality Index reached 27% of sales. Company-wide design wins rose nearly 30% year-over-year; Automation segment new product revenue grew >70% and Medical Solutions new product sales grew ~45%.
Broad-Based Segment Strength
Medical Solutions revenue grew 15% YoY (Advanced Surgery +11%, Precision Medicine +18% driven by Keonn acquisition). Robotics & Automation revenue +7% YoY with bookings up 50%. Precision Manufacturing returned to mid-single-digit revenue growth (+6%) with its fifth consecutive quarter of double-digit bookings growth.
Exposure to GenAI/Semiconductor Tailwinds
Approximately 15% of company revenue was tied to GenAI-related data center and advanced semiconductor applications in Q1, which grew ~20% YoY and are expected to accelerate. Company joined NVIDIA Halos AI Systems Inspection Lab, underscoring positioning in safety-validated AI-driven robotics.
Operational & Strategic Progress
Management is executing a regional manufacturing consolidation (two facility closures on track for Q2) to drive H2 gross margin improvement, maintains a deep acquisition pipeline and plans disciplined capital deployment to accelerate strategic priorities.